Benson Seth Benjamin 4

What Happened Benson Seth Benjamin, a director of Harvard Bioscience, was granted 16,556 restricted stock units (RSUs) on June 9, 2026. The grant is recorded at $0.00 per share (transaction code A — award/acquisition). These RSUs vest in full either immediately prior to the company’s next annual meeting or one year from the grant date, whichever is earlier.

Key Details

• Transaction date and type: 2026-06-09 — Grant/Award of 16,556 RSUs at $0.00 (Form 4 filed 2026-06-11).
• Shares beneficially owned after transaction: 27,556 total (includes the 16,556 RSUs plus 11,000 shares already beneficially owned, per filing).
• Footnote highlights:
  • F1: Vesting: full vesting immediately before next annual meeting or one year from grant, whichever is earlier.
  • F2: The reported beneficial ownership combines this award and 11,000 previously owned shares.
  • F3: A 10-for-1 reverse stock split effective March 13, 2026 adjusted prior reported quantities (numbers shown are post-split).
• Timeliness: Filed June 11, 2026 for a June 9 transaction — reported within the normal two-business-day Form 4 window.

Context This was a compensation award (RSUs), not an open-market purchase or sale; RSUs typically reflect compensation or retention incentives and do not represent immediately tradeable shares until vested. No exercise, sale, or cashless transaction occurred in this reported grant.